The protocol is currently being used to study Tecentriq and Cotellic in children, but Genentech wants to use it to evaluate drugs across its oncology portfolio.
The laboratory will employ dedicated computational biologists and bioinformaticians to analyze genomic datasets for ALSF-funded researchers and other scientists.
FedCentric also plans to offer a combined hardware and software solution as well as a cloud-based software option for genomics customers.
The researchers plan to enroll 400 patients in the pilot, with the goal of increasing the availability of targeted therapies to pediatric cancer patients.
Cavatica is a project of CHOP's Center for Data Driven Discovery in Biomedicine and is part of its commitment to the Precision Medicine Initiative.
The consortium will focus on using molecular profiling technologies to enroll pediatric cancer patients in immunotherapy clinical trials.
The new gene panel is based on DNA and RNA sequencing research and will utilize Thermo's Ion Torrent platform and Ion AmpliSeq technology.
Using genomic data for pediatric low-grade gliomas, researchers uncovered a MYB-QKI fusion that appears to drive angiocentric glioma development.
The Center for Data Driven Discovery in Biomedicine is a joint project of CHOP Research Institute and CHOP's Department of Biomedical Health and Informatics.
Both studies found that about 40 percent of pediatric cancer patients have mutations with potential clinical significance, either for diagnosis or treatment.
The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.
Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.
Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.
In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.